T-cell immunotherapy with a chimeric receptor against CD38 is effective in eradicating chemotherapy-resistant B-cell lymphoma cells overexpressing survivin induced by BMI-1

Blood Cancer Journal

Volumn 2, Issue 6, 2012, Pages

  Bhattacharyya, J ^a   Mihara, K ^a   Kitanaka, A ^b   Yanagihara, K ^c   Kubo, T ^c   Takei, Y ^d   Kimura, A ^a   Takihara, Y ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

^c YASUDA WOMEN'S UNIVERSITY   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BMI1 PROTEIN; CD38 CHIMERIC ANTIGEN RECEPTOR ANTIBODY; SURVIVIN; UNCLASSIFIED DRUG;

B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; HUMAN; HUMAN CELL; LETTER; LYMPHOMA CELL LINE; PROTEIN EXPRESSION;

EID: 84864048421     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2012.21     Document Type: Letter

References (17)

1. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-fromcancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005; 115: 1503-1521. (Pubitemid 40814659)
2. Mihara K, Chowdhury M, Nakaju N, Hidani S, Ihara A, Hyodo H et al. Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis. Blood 2006; 107: 305-308. (Pubitemid 43053556)
3. Mohty M, Yong AS, Szydlo RM, Apperley JF, Melo JV. The polycomb group. BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood 2007; 110: 380-383. (Pubitemid 47026858)
4. Bhattacharyya J, Mihara K, Ohtsubo M, Yasunaga S, Takei Y, Yanagihara K et al. Overexpression of BMI-1 correlates with drug resistance in B-cell lymphomas through the stabilization of survivin expression. Cancer Sci 2012; 103: 34-41.
5. Fang SC, Cassidy A, Christiani DC. A systematic review of occupational exposure to particulate matter and cardiovascular disease. Int J Environ Res Public Health 2010; 7: 1773-1806.
6. Fu K, Weisenburger DD, Choi WW, Perry KD, Smith LM, Shi X et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008; 26: 4587-4594.
7. Nyman H, Adde M, Karjalainen-Lindsberg ML, Taskinen M, Berglund M, Amini RM et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007; 109: 4930-4935. (Pubitemid 46827791)
8. Saito B, Shiozawa E, Usui T, Nakashima H, Maeda T, Hattori N et al. Rituximab with chemotherapy improves survival of non-germinal center type untreated diffuse large B-cell lymphoma. Leukemia 2007; 21: 2563-2566. (Pubitemid 350148910)
9. Xia ZG, Xu ZZ, Zhao WL, Zhao SQ, Ding F, Chen Y et al. The prognostic value of immunohistochemical subtyping in Chinese patients with de novo diffuse large B-cell lymphoma undergoing CHOP or R-CHOP treatment. Ann Hematol 2010; 89: 171-177.
10. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 2005; 24: 2121-2143. (Pubitemid 40516580)
11. Mihara K, Yanagihara K, Takigahira M, Imai C, Kitanaka A, Takihara Y et al. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma. J Immunother 2009; 32: 737-743.
12. Mihara K, Yanagihara K, Takigahira M, Kitanaka A, Imai C, Bhattacharyya J et al. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti- CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma. Br J Haematol 2010; 151: 37-46.
13. Schuurman HJ, van Baarlen J, Huppes W, Lam BW, Verdonck LF, van Unnik JA. Immunophenotyping of non-Hodgkin's lymphoma. Lack of correlation between immunophenotype and cell morphology. Am J Pathol 1987; 129: 140-151. (Pubitemid 17157779)
14. Stevenson GT. CD38 as a therapeutic target. Mol Med 2006; 12: 345-346. (Pubitemid 46489831)
15. Le Gouill S, Talmant P, Touzeau C, Moreau A, Garand R, Juge-Morineau N et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica 2007; 92: 1335-1342. (Pubitemid 350144150)
16. Porter DL, Levine BL, Kalos M, Bagg A. June CH. Chimeric antigen receptormodified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365: 725-733.
17. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3: 95ra73.